Abstract
Programmed cell death-1 (PD-1) / programmed cell death-ligand 1 (PD-L1) inhibitors have shown efficacy for advanced non-small cell lung cancer (NSCLC) and are now standard therapies for patients with advanced-stage NSCLC. It is unknown whether pembrolizumab monotherapy (MONO) or pembrolizumab plus chemotherapy (COMB) should be selected for patients exhibiting high PD-L1 expression (tumour proportion score [TPS] of 50% or greater). However, there are few reports on the current status of first-line treatment with pembrolizumab for highly PD-L1 expressing NSCLC in clinical practice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
